[Management of enzalutamide, a new hormonal therapy].
Enzalutamide (MDV3100) is a non-steroidal antiandrogen of second generation that has shown efficacy in metastatic castration-resistant prostate cancer (mCRPC). The study AFFIRM demonstrated a statistically significant increase in overall survival among patients who have progressed following a docetaxel chemotherapy. Based on these results, a marketing authorization for enzalutamide has been granted. The enzalutamide has been shown to be generally well tolerated. Other trials are underway to evaluate its earlier use in the management of mCRPC. A pivotal registration phase III study (PREVAIL) is ongoing to investigate the effectiveness of enzalutamide in patients who have not yet received chemotherapy.
Institut Curie, 26, rue d'Ulm 75248 Paris cedex 05, France.
Philippe
P
Beuzeboc
Institut Curie, Hôpital René-Huguenin, 35, rue Dailly, 92100 Saint-Cloud, France.
Marc-Antoine
MA
Benderra
Institut Curie, Hôpital René-Huguenin, 35, rue Dailly, 92100 Saint-Cloud, France.
Thibault
T
de La Motte Rouge
D000069501:Abiraterone Acetate; D000726:Androgen Antagonists / Q000627:therapeutic use*; D000730:Androstadienes / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001549:Benzamides; D002986:Clinical Trials as Topic; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008297:Male; D009570:Nitriles; D010669:Phenylthiohydantoin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000188:drug therapy*
D000726:Androgen Antagonists; D000730:Androstadienes; D018931:Antineoplastic Agents, Hormonal; D001549:Benzamides; D009570:Nitriles; D010669:Phenylthiohydantoin; C540278:enzalutamide; D000069501:Abiraterone Acetate
MDV3100; abiraterone acetate; androgen-receptor; enzalutamide; metastatic hormone-refractory prostate cancer